Uday R Popat, M.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
About Dr. Popat
Present Title & Affiliation
Primary Appointment
Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Myelofibrosis: Reduced intensity allogeneic transplantation(SCT) for myelofibrosis: This is a novel study, first protocol in this disease at MDACC and the largest single center study, which is still accruing patients. Our preliminary results are encouraging. If these hold over a period of time, this should become standard of care and establish allogeneic transplant as a viable, curative therapy. In a separate study we showed that long term remission was possible in patients with AML post MF after SCT. This finding has not been previously reported.
Multiple Sclerosis: My previous study and current ongoing study at MDACC will go some way in establishing a role for autologous transplantation in this disease. Our study on allogeneic transplantation for patients with ALS was novel and although negative for clinical endpoints did show significant trafficking of donor hematopoietic stem cells to diseased areas in central nervous system.
Imapct of comorbidities on SCT: To identify patients most suitable for allo transplant and to identify the most suitable transplant strategy for patients with comorbidities.
Risk factors predicting stem cell mobilization failure.
Education & Training
Degree-Granting Education
| 2016 | Rice University, Houston, TX, USA, MBA, Business Administration |
| 2003 | Royal College of Pathologists, London, GBR, FRCPath, Hematology |
| 1995 | Royal College of Pathologists, London, GBR, MRCPath, Hematology |
| 1994 | Royal College of Pathologists, London, GBR, Dip RCPath, Hematology |
| 1991 | Royal College of Physicians, London, GBR, MRCP, Internal Medicine |
| 1988 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bombay, IND, MD, Internal Medicine |
| 1983 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bombay, IND, MB, BS, Med School |
Postgraduate Training
| 1997-1999 | Residency, Internal Medicine, Baylor College of Medicine, Houston, TX |
| 1996-1997 | Fellowship, Hematology and Medical Oncology, Baylor College of Medicine, Houston, TX |
| 1995-1996 | Fellowship, Bone Marrow Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1994-1995 | Fellowship, Bone Marrow Transplant, Royal Free Hospital and School of Medicine University of London, London |
| 1983-1988 | Internship and Residency, Internal Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, University of Bombay, Bombay |
Board Certifications
| 2001 | American Board of Internal Medicine, Medical Oncology |
| 2001 | American Board of Internal Medicine, Hematology |
| 2000 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2011
Administrative Appointments/Responsibilities
Associate Program Director, Department of Stem Cell Transplant Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Institutional Committee Activities
Member, Search Committee for Neuro-Oncology, 2019 - Present
Member, Operative task force 6, 2019 - Present
Member, Urgent care task force, 2019 - Present
Member, Cost accounting committee, 2019 - Present
Member, Executive Committee of Medical Staff, 2018 - Present
Member, PRS Faculty Compensation & Benefit Advisory Committee, 2017 - Present
Member, Operational Priority 2 Financial Sustainability, 2017 - Present
Member, TMC 3 Taskforce, 2017 - Present
Member, Executive Institutional Compliance Committee, 2017 - 2018
Member, Faculty Senate Executive Committee, 2015 - 2017
Member, Credentials Committee of the Medical Staff, 2015 - Present
Quality Officer, Quality Officer for Stem Cell Transplantation and Cellular Therapy, 2011 - Present
Member, Clinical Research Committee - CRC 2, 2011 - 2015
Alternate Member, Credentials Committee of the Medical Staff, 2011 - 2015
Member, Computerized Provider Order Entry (CPOE) Steering Committee, 2010 - Present
Member, Faculty Senate, 2010 - 2018
Member, Infection Control Committee, 2008 - 2013
Member, Infection Control Core Group, 2008 - 2013
Honors & Awards
| 2020 | Best Abstract Award, 2020 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR |
| 2009 | Best Doctors in America, Best Doctors, Inc |
Selected Publications
Peer-Reviewed Articles
- Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
- Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson AL, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin DC, Nieto Y, Oran B, Saini NY, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
- Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. JCO Oncol Pract 19(3):e417-e427, 2023. e-Pub 2023. PMID: 36626702.
- Szewczyk NA, Ngo-Huang A, Soones TN, Adekoya LM, Fontillas RC, Ferguson JK, Gale-Capps HE, Kurse BC, Lindsay RJ, Ombres R, Rivera ZR, Gulbis AM, Neumann JL, Braveman BH, Marin D, Shigle TL, Whited L, Wallis WD, Sullivan H, Cao L, Champlin RE, Shpall E, Popat UR. Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther 27(12):1008-1014, 2021. e-Pub 2021. PMID: 34537421.
- Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
- Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
- Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
- Joseph J, Popat U. Improving Survival After Transplant in Myelofibrosis. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S72-S73, 2020. PMID: 32862877.
- Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
- Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. e-Pub 2019. PMID: 31296578.
- Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. PMID: 30389035.
Abstracts
- Srour SA, Kongtim P, Chen J, Rondon G, Hosing C, Popat U, Bashir Q, Qazilbash M, Kebriaei P, Petropoulos. Second allogeneic stem cell transplantation with haploidentical grafts for post-transplant relapse. 25th EHA Virtual Congress 4(S1):645, 2020.
Grant & Contract Support
| Title: | High dose immunosuppression and autologous transplantation for multiple sclerosis (HALT MS) study |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Title: | Eltrombopag for post transplant thrombocytopenia |
| Funding Source: | GlaxoSmithKline |
| Role: | Principal Investigator |
| Title: | Allogeneic stem cell transplantation for myelofibrosis using reduced intensity busulfan and fludarabine conditioning |
| Funding Source: | Otsuka Pharmaceutical Company Ltd |
| Role: | Principal Investigator |
| Title: | Novel Correlative Studies for Ongoing MD Anderson Eltrombopag Trials |
| Funding Source: | Novartis |
| Role: | Co-Investigator |
| Title: | Pacritinib Prior to Transplant for Patients with Myeloproliferative Neoplasms (MPN) |
| Funding Source: | CTI BioPharma Corp |
| Role: | Principal Investigator |
| Title: | Blu/Flu and Sorafenib in AML/MDS |
| Funding Source: | Bayer Pharmaceutical |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified August 30, 2024